Methylnaltrexone Bromide Suppliers & Bulk Manufacturers
Available Forms: Tablet / Injection
Available Strengths: 12 mg/mL , 8 mg/mL , 450 mg
Reference Brands: Relistor (USA)
Category:
Gastrointestinal Drugs
Methylnaltrexone Bromide is available in Tablet / Injection
and strengths such as 12 mg/mL , 8 mg/mL , 450 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Methylnaltrexone Bromide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Methylnaltrexone Bromide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Methylnaltrexone bromide is a peripherally acting mu-opioid receptor antagonist used to relieve constipation caused by opioid medications, commonly referred to as opioid-induced constipation (OIC). It is marketed under the brand name Relistor and is indicated for adult patients experiencing constipation due to opioid use for chronic pain, including pain associated with cancer, cancer treatment, or other advanced illnesses.
This medication works by selectively binding to opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, which allows it to block the constipating effects of opioids while preserving their pain-relieving properties. Methylnaltrexone bromide can be administered subcutaneously for rapid relief or orally for chronic management, depending on the patient’s condition and treatment plan.
By targeting peripheral opioid receptors, methylnaltrexone bromide effectively restores bowel function and provides relief from constipation without compromising analgesia. Its mechanism and safety profile make it a valuable option for patients who require long-term opioid therapy and need to maintain gastrointestinal regularity under medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing